What were the key takeaways from Autolus Therapeutics’s earnings call?

What factors drove the changes in Autolus Therapeutics's revenue and profit?

What is Autolus Therapeutics's latest dividend and current dividend yield?

What does Autolus Therapeutics do and what are its main business segments?

What is the revenue and EPS growth rate for Autolus Therapeutics year over year?

What were the key takeaways from Autolus Therapeutics's earnings call?

Did Autolus Therapeutics beat or miss consensus estimates last quarter?

What guidance did Autolus Therapeutics's management provide for the next earnings period?

- **Revenue Growth**: 2025 AUCATZYL revenue $74.3 million; 2026 guidance $120-135 million with >80 centers. Gross margins to turn positive in 2026.
- **Clinical Success**: ROCCA real-world data shows 92% remission at day 28, matching clinical trial safety and efficacy.
- **Pipeline Momentum**: CATULUS pediatric ALL Phase II, CARLYSLE lupus nephritis, and BOBCAT MS trials advancing; LUMINA pivotal study 2028 readout.
- **Financial Health**: $300.7 million cash; 2026 operations funded. Accounting change aligns revenue/cost timing with second dose.

**【CEO Summary Section】**
- **2025 Revenue and Launch Progress**: Achieved $74.3 million in AUCATZYL revenue with 67 activated centers. Reiterated 2026 guidance of $120-135 million net revenue, targeting >80 centers by year-end. Gross margins expected to turn positive in 2026 due to scale and operational efficiency.
- **Real-World Data (ROCCA Consortium)**: 96 patients treated, 91 infused, with 92% complete remission at day 28. Safety profile aligned with clinical trials (59% CRS Grade 1/2, 3% ICANS Grade 3).
- **Pipeline Expansion**: CATULUS pediatric ALL study (Phase II expansion), CARLYSLE lupus nephritis trial (Phase I), and BOBCAT progressive MS study (Phase I) underway. LUMINA lupus nephritis pivotal study expected to read out in 2028.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Net product revenue $23.3 million (Q4) and $74.3 million (FY2025). Cost of sales $25.3 million (Q4) due to commercial manufacturing scale-up. GAAP net loss $90.3 million (Q4) driven by R&D and SG&A expenses.
- **Accounting Change**: Revenue recognized upon second dose administration; no material impact on financials. Cash position $300.7 million, sufficient for operations into Q4 2027.
- **2026 Outlook**: Positive gross margin shift, focusing on U.S. expansion with U.K. launch in early stages.

**【Q&A Key Highlights】**
- **Market Share and U.K. Contribution**: U.S. dominates 2026 guidance; U.K. contribution too early to quantify. EU market access discussions ongoing but no 2026 revenue expected.
- **Clinical Trial Updates**: LUMINA lupus nephritis study enrolling in U.S. and U.K.; BOBCAT MS trial first data late 2026. CARLYSLE lupus nephritis Phase I data update Q4 2026.
- **Gross Margin Trajectory**: 2026 gross margin improvement driven by volume and operational efficiency; 2027+ expansion opportunities with Cellares platform for scalability.
- **Patient Dosing and Revenue Recognition**: Patients receiving only one dose handled via cash receipts; no material impact on 2026 guidance.


Autolus Therapeutics Ltd (AUTL) Q4 2025 Earnings Call Transcript

- **Q3 Sales Beat Expectations**: $21.1M in AUCATZYL revenue with $7.6M deferred revenue, signaling strong Q4 demand. 
- **Market Leadership Solidified**: 20% CAR-T share in active centers, expanding to 60+ treatment centers. 
- **Operational Efficiency Push**: New leadership team driving $367M cash runway for 2026 expansion. 
- **Autoimmune Pipeline Momentum**: LUMINA (lupus nephritis) and BOBCAT (MS) trials initiated, with CARLYSLE showing 5/6 remissions. 
- **Gross Margin Outlook**: Improvements expected through 2026 as manufacturing scales and automation implemented.

**【CEO Summary Section】**
- Achieved $21.1 million in net sales for AUCATZYL in Q3 2025, with deferred revenue of $7.6 million, indicating strong demand for Q4. 
- Market leadership in relapsed/refractory B-ALL with 20% CAR-T market share in active centers, targeting expansion to 60+ treatment centers. 
- Manufacturing success rate >90%, with >90% patient access coverage across U.S. 
- Expanded pipeline into autoimmune diseases: Phase II lupus nephritis trial (LUMINA) and Phase I MS trial (BOBCAT) initiated. 
- New leadership appointments to drive operational efficiency and cost savings. 

**【CFO Financial Commentary】**
- Q3 2025 net loss of $79.1 million, improved from $82.1 million in Q3 2024, with cash reserves of $367.4 million. 
- Cost of sales $28.6 million, driven by commercial manufacturing scale-up. 
- R&D expenses down 25% YoY to $27.9 million due to shifting costs to COGS. 
- SG&A up 33% YoY to $36.3 million, reflecting commercialization headcount growth. 
- Expect gross margin improvements as volumes increase and operational efficiencies realized. 

**【Q&A Highlights】**
- CMS coding delay impacted Q2 patient enrollment, resolved in Q3 with stable Q3 sales. 
- Deferred revenue trends indicate strong Q4 growth potential, though holiday season may cause temporary slowdown. 
- Gross margin improvements expected through 2026 as manufacturing scales and automation implemented. 
- Pediatric ALL trial (CATULUS) Phase II initiation with FDA agreement on trial design. 
- Lupus nephritis trial (CARLYSLE) shows 5/6 patients achieving DORIS remission with favorable safety profile. 
- Competitive positioning in autoimmune space supported by unique CAR-T design targeting B cells.

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

- **U.S. Launch Momentum**: Q2 sales $20.9 million, 60+ centers target by year-end. CMS reimbursement adjustments resolved by Q4.
- **Global Strategy**: No EU sales 2025-2026; U.K. NICE negotiations ongoing. Germany launch contingent on economic viability.
- **Clinical Excellence**: FELIX data shows 38% long-term remission, 40% overall survival. Lupus nephritis Phase II trial to start in H2.
- **Financial Health**: Net loss $47.9 million, cash $454.3 million. Gross margin improvement expected with scale.


**【CEO Summary Section】**
- **Q2 Product Sales**: $20.9 million, bringing H1 total to $29.9 million. U.S. market coverage expanded to 46 centers, with 90% of medical lives covered, targeting 60+ centers by year-end.
- **CMS Reimbursement Impact**: A split reimbursement model delayed patient enrollment in Q2 but is expected to resolve by Q4. CMS granted a permanent HCPCS code in July.
- **Regulatory Progress**: Conditional marketing authorization in the U.K. (April) and EU (July). No EU sales expected in 2025-2026 due to economic viability assessments.
- **FELIX Data Update**: 38% of responding patients remain in remission at 32.8 months, with median duration of response 42.6 months and 40% overall survival plateau.
- **Future Pipeline**: Pediatric obe-cel Phase I/II study expansion, ISTs for frontline ALL, and Phase II lupus nephritis trial with registrational intent.

**【CFO Financial Commentary】**
- **Q2 Financials**: Net product revenue $20.9 million (vs. $9 million Q1). Cost of sales $24.4 million, including deferred revenue of $2.1 million.
- **Expenses**: R&D down 25% to $27.4 million (vs. $36.6 million 2024), SG&A up 38% to $30.3 million (due to commercialization headcount). Net loss $47.9 million (vs. $58.3 million 2024).
- **Cash Position**: $454.3 million (vs. $588 million end-2024), impacted by delayed U.K. R&D tax credit.

**【Q&A Key Highlights】**
- **Germany Launch**: Disciplined approach to EU market access; 8/18 cell therapies not launched in Europe. Germany's reference pricing framework complicates sequencing.
- **Reimbursement Cadence**: CMS split reimbursement adjustments resolved by Q4; no impact on long-term gross margin trajectory.
- **Gross Profit Outlook**: Volume-driven improvement expected in H2; no specific timing for breakeven.
- **U.S. Center Expansion**: 46 centers operational, with high reorder rates and physician adoption. Training period minimal, focusing on high-volume centers.
- **Autoimmune Trials**: Phase II lupus nephritis trial to dose first patients in H2; Phase I MS trial open for enrollment. ACR 2025 to present 6+ month follow-up data on SLE patients.


Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

- **Strong Q1 Launch**: $9 million in AUCATZYL revenue with 39 centers activated, 90% U.S. patient coverage, and CMS outpatient reimbursement enablement.
- **Expansion and Pipeline**: 60-center U.S. expansion, EU/UK launches, and Phase 1/2 trials in lupus nephritis and MS planned for 2025.
- **Financial Strength**: $516 million cash, no material tariff risk, and consistent manufacturing turnaround times (16 days).
- **Autoimmune Differentiation**: CARLYSLE study shows 5/6 lupus nephritis patients achieve remission with no ICANS, positioning AUCATZYL for first-in-class status.

**【CEO Summary Section】**
- **Q1 Revenue and Launch Momentum**: Recognized $9 million in product revenue from AUCATZYL, with 39 centers activated and 90% U.S. patient coverage. CMS coding updates enable outpatient reimbursement for government programs.
- **Expansion Plans**: Targeting 60 centers by year-end to cover ~90% of U.S. patients. EU market authorization decision expected in H2 2025, with UK launch preparations underway.
- **Autoimmune Disease Potential**: Early data in lupus nephritis (CARLYSLE study) shows 5/6 patients achieving renal remission with no ICANS. Phase 1/2 trial in progressive MS and lupus nephritis planned for 2025.

**【CFO Financial Commentary】**
- **Financial Performance**: Q1 2025 net product revenue $9 million, cost of sales $18 million (includes deferred revenue). R&D expenses $26.7 million (down 13% YoY), SG&A $29.5 million (up 62% YoY due to commercialization). Cash balance $516.6 million, supporting 2025 trials.
- **Revenue Recognition**: CMS split dosing impacts timing, but ~5.5% of patients historically did not complete both doses. Average administration interval 9 days, with no material full-year sales impact expected.

**【Q&A Key Highlights】**
- **Tariff Risks**: Blood-derived products typically exempt from tariffs. FDA engagement on lupus nephritis trial design remains constructive, with focus on severe patient populations.
- **Manufacturing Efficiency**: Median turnaround time 16 days (vs. 21 days in FELIX trial). Consistent product quality and persistence observed across indications.
- **Competitive Position**: AUCATZYL's safety profile (no REMS requirement) and first-to-market potential in lupus nephritis differentiate it from competitors.

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

- **U.S. Launch Progress**: 33 centers active, covering 60% of patients; 60 centers expected by year-end.
- **Clinical Impact**: 45-50% EFS and 50% OS in relapsed/refractory ALL; no high-grade toxicities in low-tumor-burden patients.
- **Financial Strength**: $588M cash; $30M milestone payment from Blackstone.
- **Global Expansion**: EU/U.K. approvals anticipated in H2 2025; NICE assessment ongoing.
- **Pipeline Momentum**: AUTO1/22 interim data (6 patients) and pediatric ALL trial updates at April 23 R&D Day.

**【CEO Overview】**
- **Commercial Launch Momentum**: Aucatzyl achieved U.S. FDA approval in November 2024, with 33 active centers as of March 19, covering ~60% of the target patient population. By year-end, 60 centers are expected to be operational, reaching the majority of U.S. patients.
- **Clinical Efficacy**: Phase 3 FELIX study showed 45-50% event-free survival (EFS) and 50% overall survival (OS) in relapsed/refractory ALL. Patients with low tumor burden (<5%) had no high-grade CRS/ICANS events.
- **Global Expansion**: Regulatory filings in Europe and the U.K. completed; EU and U.K. approvals anticipated in H2 2025. NICE assessment underway for U.K. reimbursement.
- **Pipeline Progress**: AUTO1/22 (autoimmune) interim data from 6 patients to be shared at April 23 R&D Day; pediatric ALL study (PY1) enrollment progressing.

**【CFO Financial Update】**
- **Cash Position**: $588M at year-end (vs. $239M in 2023), bolstered by $600M from BioNTech collaboration and equity financing.
- **Revenue & Costs**: Cost of sales $11.4M (post-approval manufacturing). R&D expenses $138.4M (+5.9% YoY), driven by commercial manufacturing and headcount. SG&A $101.1M (+117% YoY) due to commercialization.
- **Milestones**: $30M milestone from Blackstone for U.S. approval; $10M regulatory payment to UCLB.

**【Q&A Highlights】**
- **Demand & Outpatient Use**: Early center activation reflects strong physician interest; outpatient administration potential noted but too early to quantify.
- **Manufacturing Efficiency**: Commercial manufacturing aligns with clinical trial performance; vein-to-vein time consistent with 16-day target.
- **Regulatory & Tariffs**: No immediate tariff impact expected; EU and U.K. approvals on track for H2 2025.
- **SLE Trial Insights**: AUTO1/22 interim data focus on safety, B-cell depletion, and disease score metrics; long-term follow-up planned for H2 2025.


Actual					-0.6	-0.62	-0.72	-0.82	-0.53	-0.47	-0.47	-0.51	-0.41	-0.46	-0.47	-0.245	-0.23	-0.26	-0.26	-0.44	-0.24	-0.22	-0.31	-0.09	-0.26	-0.18	-0.3	-0.34
Forecast					-0.7417	-0.7089	-0.7067	-0.7656	-0.6044	-0.4986	-0.5052	-0.3856	-0.4929	-0.42	-0.4718	-0.2686	-0.2673	-0.2235	-0.2495	-0.2529	-0.0801	-0.1945	-0.2143	-0.2058	-0.2435	-0.2306	-0.2144	-0.2599
Surprise	0.00%	0.00%	0.00%	0.00%	+19.10%	+12.54%	-1.88%	-7.11%	+12.31%	+5.74%	+6.97%	-32.26%	+16.82%	-9.52%	+0.38%	+8.79%	+13.95%	-16.33%	-4.21%	-73.98%	-199.63%	-13.11%	-44.66%	+56.27%	-6.78%	+21.94%	-39.93%	-30.82%

AUTL

AUTL fundamentals

AUTL Q4 2025 Earnings

Earnings Call

You can ask Aime

AUTL

AUTL fundamentals

AUTL Q4 2025 Earnings

Earnings Call

AUTL Earnings Call Summary for Q4/20258:30 AM on Mar 27, 2026

AUTL Earnings Call Summary for Q3/20258:30 AM on Nov 12, 2025

AUTL Earnings Call Summary for Q2/20258:30 AM on Aug 12, 2025

AUTL Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

AUTL Earnings Call Summary for Q4/20248:30 AM on Mar 20, 2025

You can ask Aime